Back to top

Compugen to Present a Pooled Analysis of COM701 Phase 1 trials in Platinum Resistant Ovarian ...

Compugen to Present a Pooled Analysis of COM701 Phase 1 trials in Platinum Resistant Ovarian Cancer at ESMO 2025 | CGEN Stock News

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Compugen Ltd. (CGEN)